Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 6
2014 9
2015 12
2016 10
2017 23
2018 20
2019 12
2020 11
2021 4
2022 10
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35882585

101 results

Results by year

Filters applied: . Clear all
Page 1
Nuts and Bolts of 223Ra-dichoride Therapy.
Grady E. Grady E. J Nucl Med Technol. 2022 Jul 26:jnmt.122.263812. doi: 10.2967/jnmt.122.263812. Online ahead of print. J Nucl Med Technol. 2022. PMID: 35882585
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, Komai Y, Numao N, Yuasa T, Inoue M, Ushijima H, Kudo S, Shimano Y, Nakamura Y, Uchida Y, Uehara S, Tanaka H, Yaegashi H, Izumi K, Yokoyama M, Matsuoka Y, Yoshioka Y, Konishi K, Nakanishi K, Nagahara A, Hirakawa A, Koike R, Koga F, Nishimura K, Mizokami A, Yonese J, Kageyama Y, Yoshimura R, Fujii Y. Yoshida S, et al. BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z. BMC Urol. 2023. PMID: 36879257 Free PMC article. Clinical Trial.
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.
O'Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, Schmall A, Sandström P, Verholen F, Shore N. O'Sullivan JM, et al. Front Med (Lausanne). 2022 Dec 22;9:fmed-09-1070392. doi: 10.3389/fmed.2022.1070392. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619649 Free PMC article. Review.
Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer.
Takeda K, Kawasaki Y, Sakayauchi T, Takahashi C, Katagiri Y, Tanabe T, Ishikawa Y, Fujimoto K, Kubozono M, Kozumi M, Abe K, Narazaki K, Tasaka S, Umezawa R, Yamamoto T, Takahashi N, Suzuki Y, Kishida K, Omata S, Ito A, Jingu K. Takeda K, et al. Asia Ocean J Nucl Med Biol. 2023;11(1):13-22. doi: 10.22038/AOJNMB.2022.67136.1468. Asia Ocean J Nucl Med Biol. 2023. PMID: 36619192 Free PMC article.
Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, Kono Y, Tamaki Y, Seko-Nitta A, Ishiwata Y, Ito K, Toriihara A, Watanabe S, Hosono M, Miyake H, Yamamoto S, Narita M, Daimon T, Yamakado K. Kitajima K, et al. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1487-1498. doi: 10.1007/s00259-022-06082-3. Epub 2022 Dec 21. Eur J Nucl Med Mol Imaging. 2023. PMID: 36539508
AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).
Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, Chin KY, Emmerson B, Owen KL, Parker BS, Fettke H, Furic L, Azad AA, Hofman MS. Kostos L, et al. Front Med (Lausanne). 2022 Nov 18;9:1059122. doi: 10.3389/fmed.2022.1059122. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36465905 Free PMC article.
101 results